Catalent, Inc. (NYSE:CTLT) Given Average Rating of “Hold” by Brokerages

Catalent, Inc. (NYSE:CTLT) has received an average rating of “Hold” from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Seven research analysts have rated the stock with a hold rating. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $63.40.

Several equities research analysts recently weighed in on CTLT shares. Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. StockNews.com upgraded shares of Catalent from a “sell” rating to a “hold” rating in a research report on Monday, December 2nd. William Blair restated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Finally, Robert W. Baird reaffirmed a “neutral” rating and issued a $63.50 target price on shares of Catalent in a report on Tuesday, September 24th.

Catalent Stock Performance

Shares of NYSE:CTLT opened at $61.83 on Monday. Catalent has a 12-month low of $36.74 and a 12-month high of $62.20. The company’s 50 day moving average price is $60.07 and its two-hundred day moving average price is $58.74. The firm has a market cap of $11.22 billion, a PE ratio of -27.36, a PEG ratio of 2.46 and a beta of 1.15. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38.

Catalent (NYSE:CTLT) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. Catalent’s revenue was up 4.2% on a year-over-year basis. During the same quarter last year, the business earned ($0.10) EPS. Equities research analysts predict that Catalent will post 0.84 earnings per share for the current year.

Insider Transactions at Catalent

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the transaction, the director now directly owns 10,835 shares in the company, valued at approximately $646,849.50. This represents a 20.54 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the transaction, the insider now directly owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. This represents a 5.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 5,114 shares of company stock worth $305,931. Corporate insiders own 0.31% of the company’s stock.

Institutional Trading of Catalent

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CTLT. Swedbank AB acquired a new stake in shares of Catalent during the first quarter worth $1,659,000. DekaBank Deutsche Girozentrale raised its position in shares of Catalent by 2.4% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 31,445 shares of the company’s stock worth $1,763,000 after acquiring an additional 732 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of Catalent by 25.9% in the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after purchasing an additional 212 shares during the period. DNB Asset Management AS lifted its stake in Catalent by 10.4% in the second quarter. DNB Asset Management AS now owns 30,598 shares of the company’s stock valued at $1,721,000 after buying an additional 2,887 shares during the period. Finally, Thurston Springer Miller Herd & Titak Inc. bought a new position in Catalent during the second quarter worth $42,000.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.